Goldgroup Mining has increased its private placement offering from $75 million to $125 million due to strong investor demand. The funds will support production growth, exploration, project development, and potential acquisitions across its mining assets in Mexico and the US. This capital raise strengthens Goldgroup's balance sheet, enabling it to pursue its goal of becoming a leading intermediate precious-metals producer in the Americas. The offering is expected to close by September 30, 2026, pending regulatory approvals.
Goldgroup Mining's private placement increase to $125 million provides context for basic materials sector activity. For readers following this sector, here is Pluang's market snapshot as of Sep 14, 2026 19:12 WIB: of 32 priced Basic Materials-sector US stocks tradable on Pluang, 8 rose and 23 fell today. Notable prices include SBSW at USD 11.81 with a -5.82% change, GFI at USD 43.09 with a -4.46% change, and FCX at USD 67.97 with a -4.36% change.
Kering has released its monthly statement detailing the total number of shares and voting rights as of October 15, 2026. The company reported 123,420,778 total shares and 176,815,752 theoretical voting rights, with 176,046,302 exercisable voting righ...
Kering published its monthly update on October 15, 2026, reporting a total of 123,420,778 shares composing its capital and 176,815,752 theoretical voting rights. The voting rights figure includes all shares with voting rights, including those tempora...
Pepeto, a new cryptocurrency on the Ethereum network, has quickly raised over $11.23 million in its presale, with each funding stage closing faster than the last. This momentum comes as Ethereum is predicted to reach $10,000 by the end of 2026, drive...
Opus Genetics announced FDA approval of phentolamine ophthalmic solution 0.75% for treating presbyopia, an age-related condition affecting near vision in adults. This approval, based on successful Phase 3 trials, provides a non-invasive option that i...
BlackRock, Inc. disclosed that its voting rights in pharmaceutical company Fagron NV fell below the 3% reporting threshold due to the transfer of voting securities, despite acquiring financial instruments equivalent to voting rights. As of October 12...
